Chrysin enhances antitumour immunity response through the IL‐12‐STAT4 signal pathway in the B16F10 melanoma mouse model. (13th May 2022)
- Record Type:
- Journal Article
- Title:
- Chrysin enhances antitumour immunity response through the IL‐12‐STAT4 signal pathway in the B16F10 melanoma mouse model. (13th May 2022)
- Main Title:
- Chrysin enhances antitumour immunity response through the IL‐12‐STAT4 signal pathway in the B16F10 melanoma mouse model
- Authors:
- Lu, Ran
Wang, Shuang
Jiang, Shasha
Li, Chenglin
Wang, Yashuo
Li, Ling
Wang, Yunyang
Ma, Guixin
Qiao, Hongye
Leng, Zhe
Niu, Junyun
Tian, Zibin
Wang, Bin - Abstract:
- Abstract: Chrysin (CHR) is a flavonoid with extensive pharmacological activity. The molecular formula of CHR is C15 H10 O4 . CHR is reported to have antioxidative, antitumour and antiviral functions. To evaluate its potential function as a vaccine adjuvant, we prepared a melanoma vaccine using a soluble protein extract of B16F10 melanoma cells as antigen and CHR as an adjuvant. The melanoma model was developed after two immunizations, and it was discovered that combining B16F10 soluble protein antigen‐mixed CHR vaccine could inhibit tumour growth in the mouse model, and the overall survival rate was higher than that of the B16F10 antigen vaccine alone. In vivo and in vitro experiments were conducted to determine whether CHR functioned as an adjuvant by activating antigen‐presenting cells (APCs). We discovered that CHR activated APCs both in vivo and in vitro and may enhance Th1 cell function by activating the IL12‐STAT4 signal pathway, thereby enhancing the antitumour response of cytotoxic T lymphocytes (CTLs) in vivo. Next, to verify the critical role of CD8 + T cells in suppressing melanoma development, we transplanted CD8 + T cells from immunized mice to B16F10 tumour‐bearing mice and discovered that the survival rate of tumour‐bearing mice was significantly prolonged. In summary, our experimental results indicate that CHR can be used as a potential adjuvant to enhance antigen immunogenicity, inhibit B16F10 tumour growth in mice and improve tumour immune response.
- Is Part Of:
- Scandinavian journal of immunology. Volume 96:Number 2(2022)
- Journal:
- Scandinavian journal of immunology
- Issue:
- Volume 96:Number 2(2022)
- Issue Display:
- Volume 96, Issue 2 (2022)
- Year:
- 2022
- Volume:
- 96
- Issue:
- 2
- Issue Sort Value:
- 2022-0096-0002-0000
- Page Start:
- n/a
- Page End:
- n/a
- Publication Date:
- 2022-05-13
- Subjects:
- chrysin -- melanoma -- vaccine adjuvant
Immunology -- Periodicals
571.96 - Journal URLs:
- http://www.blackwell-synergy.com ↗
http://onlinelibrary.wiley.com/journal/10.1111/(ISSN)1365-3083 ↗
http://onlinelibrary.wiley.com/ ↗ - DOI:
- 10.1111/sji.13177 ↗
- Languages:
- English
- ISSNs:
- 0300-9475
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 8087.516800
British Library DSC - BLDSS-3PM
British Library STI - ELD Digital store - Ingest File:
- 22771.xml